Chordia Therapeutics Inc is a Japan-based drug discovery venture company mainly engaged in the research and development of novel anticancer drugs for commercialization. The Company's main business is the research and development of small molecule breakthrough drugs (first-in-class) with novel actions in the field of oncology, where there is a high unmet medical need. The Company concentrates on management and research operations (exploratory, preclinical, and clinical research), particularly in the discovery, evaluation, optimization, and clinical testing of candidate compounds, and outsources basic research, active pharmaceutical ingredient and drug product manufacturing, distribution, and sales to its various external partners to advance its business.